SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution - Zahradník, Jiří; Marciano, Shir; Shemesh, Maya; Zoler, Eyal; Harari, Daniel; Chiaravalli, Jeanne; Meyer, Björn; Rudich, Yinon; Li, Chunlin; Marton, Ira; Dym, Orly; Elad, Nadav; et al. (Nature microbiology, 2021)
Keywords: 14/28; 38/23; 38/70; 38/77; 42/34; 631/181/735; 631/326/596/4130; 64; 82/47; 82/80; 82/83; 96/10; ACE2; Affinity; Amino acids; Angiotensin; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - chemistry; Angiotensin-Converting Enzyme 2 - genetics; Angiotensin-Converting Enzyme 2 - metabolism; Animals; Antiviral Agents - administration & dosage; Antiviral Agents - chemistry; Biomedical and Life Sciences; COVID-19; COVID-19 - genetics; COVID-19 - metabolism; COVID-19 - virology; COVID-19 Drug Treatment; Cricetinae; Drug Design; Drug development; Electron microscopy; Epistasis; Evolution; Evolution, Molecular; Female; Humans; Infectious Diseases; Life Sciences; Male; Medical Microbiology; Mesocricetus; Microbiology; Microbiology and Parasitology; Molecular Dynamics Simulation; Mutation; Pandemics; Parasitology; Peptidyl-dipeptidase A; Protein Binding - drug effects; Protein Domains; Receptors, Virus - genetics; Receptors, Virus - metabolism; SARS-CoV-2 - chemistry; SARS-CoV-2 - drug effects; SARS-CoV-2 - genetics; SARS-CoV-2 - metabolism; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - chemistry; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - metabolism; Spike protein; Vaccine development; Virology; Virus Internalization - drug effects